OmniXBio ($OMN)
New Paradigm for Drug Development through Decentralized Science & Bio AI Agents
$OMN Framework: The Most Advanced DeSci RWA Platform
Revolutionizing Drug Development with AI, Decentralized Technology & Computational Modelling
We use proprietary AI engine to screen and tokenize high quality biotech assets (IP as RWAs), and accelerate drug R&D with regulatory grade AI and computational modeling technologies.
By integrating decentralized technologies, we aim to create a community-driven RWA platform powered by $OMN token with full legal framework.Through our ecosystem of world leading industry and academic partners, we will bring multi-trillion dollar worth of life saving new therapies to patients faster with lower cost.
This innovative approach unlocks unparalleled investment opportunities while accelerating commercialization timelines and reducing risks inherent in traditional drug discovery.
Tokenize Biotech Assets
Convert drug candidates and IP into tradable tokens enabling fractional ownership.
Community Funding and Research
Use DAOs to fund and govern research transparently with aligned incentives. Global scientists contribute expertise for tokens.
AI Integration
Deploy AI agents and computational modeling to screen high quality assets and accelerate R&D process.
Liquidity
Enable trading of tokenized assets on a DEX, creating a liquid drug IP market.
$OMN token powers our decentralized approach to R&D. This democratizes access to biotech innovation and accelerates therapy development.
Sophisticated Risk Mitigation
Data Driven Selection
Use AI and digital twin models to screen out high-risk candidates
Virtual Validation
Model efficacy before expensive trials, significantly improve the success outlook
Structured Exits
Partner with Pharma for licensing deals or acquisitions provides liquidity earlier, and shortening the investment cycle
Structured exits with pharma partners provide liquidity before costly Phase III trials. Our AI models improve due diligence on pipeline viability.
Cutting Edge Technology Platform
Our platform combines LLMs, digital twins, and multi-omics data integration to revolutionize drug development with unprecedented accuracy.
AI Models/LLM
AI Agent
GraphRAG with LLMs for accurate scientific insights with more efficiency.
AI agents gather data, optimize and run millions of models simultaneously to screen the most promising candidates.
Digital Twin
Computational Modeling
AI driven digital twin technology to create virtual patient model and simulate biology and drug interactions.
Optimize clinical trial design to save cost and accelerate timeline.
Multi-Omics Big Data Integration
Integrate public and partner biological datasets. Incorporate genomics, proteomics, metabolomics, and spacial data for more human relevant modeling, improving R&D success.
Improving Success Rates Through AI
Better Discovery
Model pathways and mechanisms to select optimal targets for different diseases
Better Candidates
Simulate ADME and binding properties
Better Dosing
Optimize dose-response relationships
Better Cohorts
Identify ideal patient groups
Our AI & models improve mechanistic understanding of diseases and drugs. This enables better first-in-human dose selection and patient segmentation.
Real-World Assets (RWA) Framework
Types of RWAs
Drug Candidates as IPs or SPV and other IPs including patents, licenses, and proprietary research methodologies are tokenized to enable fractional ownership and funding. Research Data can also be monetized through secure tokenization.
Tokenization Process
Assets are digitized and fractionalized as tokens on the blockchain, enabling secure, transparent, and efficient transfer of ownership. This process lowers entry barriers for investors and enhances liquidity in the biotech market.
Governance & Liquidity
Token holders participate in decentralized governance, voting on project funding and milestones. A liquid secondary market facilitates trading and price discovery, ensuring dynamic investment opportunities.
Storage & Provenance
Data and asset provenance are ensured through immutable blockchain records. Secure decentralized storage solutions maintain data integrity and availability while protecting sensitive information from tampering.
Our RWA structure creates a liquid and accessible market for biotech assets, bridging the traditional gap between researchers, pharmaceutical companies, and global investors.
Our Competitive Advantage
We’ll be the first decentralized biotech platform with drug assets in clinical trials, backed by our specialized biotech focus
Proprietary AI Engine
Screen assets with higher success probability and reduce R&D costs
FDA-Approved Methods
Computational models can replace costly animal testing
Industry Network
Strong connections to bring high-quality assets on-chain
Democratized Access
Decentralized funding model opens biotech to global participants
Liquidity & Accessibility
Tokenized RWAs and a DEX provide unparalleled liquidity, making biotech investment simplified for global investors worldwide.
Partnerships
Innovation thrives through collaboration. OmniX.Bio is proud to partner with academic institutions, biotech pioneers, and pharmaceutical leaders to advance global health.
Join Our Network
Whether it's co-developing novel therapies or sharing AI-driven insights, we're committed to working together to solve the biggest challenges in drug research.
Contact Us
Have questions or want to collaborate? We’d love to hear from you.